寿仙谷 (603896.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

10.5x

Market Cap

CNY 2.93B

MomentumView details →

1D Return

−1.40%

YTD Return

−23.27%

RSI (14)

49.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

10.5x

Market Cap

CNY 2.93B

RSI (14)

49.1

MomentumView details →

1D Return

−1.40%

YTD Return

−23.27%

ProfitabilityView details →

Gross Margin

77.76%

Net Margin

−1.85%

EBITDA Margin

37.46%

ROE (TTM)

−0.50%

ROA (TTM)

−0.36%

Asset Turnover

0.19x

GrowthView details →

Revenue YoY

−5.27%

EPS YoY

—

FCF YoY

+61.46%

Revenue CAGR 3Y

−8.26%

EPS CAGR 3Y

−60.22%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

3.13x

Quick Ratio

2.65x

Div Yield

—

Div Rate

—

Div Growth 1Y

−30.77%

Financials snapshotView financials →

Revenue (TTM)

625.30M

Net Income (TTM)

−11.56M

Op. CF (TTM)

188.37M

Latest newsMore news →

Shouxiangu announced its first-half 2026 results: revenue of 276 million yuan, down 7.89% year-on-year, and net profit of 36.87 million yuan, down 43.76% year-on-year.9d ago

Similar companies

Medtide Inc.03880.HK Zai Lab LimitedZLAB MBX Biosciences, Inc. Common StockMBX Arcutis Biotherapeutics, Inc.ARQT Genor Biopharma Holdings Limited06998.HK NewAmsterdam Pharma Company N.V.NAMS Find similar companies →

Latest newsMore news →

Shouxiangu announced its first-half 2026 results: revenue of 276 million yuan, down 7.89% year-on-year, and net profit of 36.87 million yuan, down 43.76% year-on-year.9d ago